Westermark Per, Benson Merrill D, Buxbaum Joel N, Cohen Alan S, Frangione Blas, Ikeda Shu-Ichi, Masters Colin L, Merlini Giampaolo, Saraiva Maria J, Sipe Jean D
Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Amyloid. 2007 Sep;14(3):179-83. doi: 10.1080/13506120701460923.
The increasing knowledge of the exact biochemical nature of the localized and systemic amyloid disorders has made a logical and easily understood nomenclature absolutely necessary. Such a nomenclature, biochemically based, has been used for several years but the current literature is still mixed up with many clinical and histochemically based designations from the time when amyloid in general was poorly understood. All amyloid types are today preferably named by their major fibril protein. This makes a simple and rational nomenclature for the increasing number of amyloid disorders known in humans and animals.
随着对局限性和全身性淀粉样变疾病确切生化本质的认识不断增加,一套合乎逻辑且易于理解的命名法变得绝对必要。这样一种基于生化的命名法已经使用了数年,但当前文献仍与许多基于临床和组织化学的命名法混杂在一起,这些命名法来自于对淀粉样变总体认识不足的时期。如今,所有淀粉样变类型最好根据其主要纤维蛋白来命名。这为人类和动物中已知数量不断增加的淀粉样变疾病提供了一种简单而合理的命名法。